Haleon plc (HLN)vsUniverse Pharmaceuticals Inc (UPC)
HLN
Haleon plc
$9.74
+0.41%
HEALTHCARE · Cap: $44.83B
UPC
Universe Pharmaceuticals Inc
$2.25
-1.43%
HEALTHCARE · Cap: $1.28M
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 61663% more annual revenue ($11.03B vs $17.86M). HLN leads profitability with a 15.1% profit margin vs -20.6%. HLN earns a higher WallStSmart Score of 58/100 (C).
HLN
Buy58
out of 100
Grade: C
UPC
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.3%
Fair Value
$22.93
Current Price
$9.74
$13.19 discount
Intrinsic value data unavailable for UPC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
Smaller company, higher risk/reward
ROE of -7.2% — below average capital efficiency
Revenue declined 14.1%
Earnings declined 82.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Operating Margin, Free Cash Flow. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : UPC
The strongest argument for UPC centers on Price/Book, Altman Z-Score, Debt/Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : UPC
The primary concerns for UPC are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
HLN profiles as a value stock while UPC is a turnaround play — different risk/reward profiles.
UPC carries more volatility with a beta of 1.57 — expect wider price swings.
HLN is growing revenue faster at 0.6% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
HLN scores higher overall (58/100 vs 29/100), backed by strong 15.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company focused on delivering innovative health solutions across critical segments including oral care, pain relief, respiratory health, and dietary supplements. Formed from the spin-off of GlaxoSmithKline, Haleon boasts a strong portfolio of well-established brands, such as Sensodyne, Panadol, and Voltaren, solidifying its presence in the lucrative consumer health market. With a commitment to sustainability and consumer-driven innovation, the company is well-positioned to enhance health outcomes on a global scale while driving growth and delivering shareholder value through strategic investments and product advancements.
Visit Website →Universe Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Universe Pharmaceuticals INC, a pharmaceutical company, is engaged in the manufacture, marketing, distribution and sale of products derived from traditional Chinese medicine in China.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?